{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:41Z","timestamp":1777934681163,"version":"3.51.4"},"reference-count":16,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cisplatin is a widely used antineoplastic in the treatment of various types of solid cancers. The objectives of our study were to evaluate the prevalence of acute renal failure (ARF) during cisplatin-based chemotherapy and to determine the factors correlated with renal toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a prospective study that was conducted over a period of 6 months. We included patients followed for histologically confirmed solid cancer and treated with cisplatin-based chemotherapy. Assessment of renal function was made by calculating renal creatinine clearance before starting cisplatin, before every cycle, at 3 months and at 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty patients were included. The median age was 54 years (31\u201371 years). The mean cumulative dose received was 286\u2005mg\/m\u00b2 (100\u2013560\u2005mg\/m\u00b2). Twelve patients (30%) developed ARF which was grade 1 in 83% of cases. Cisplatin ARF was observed after a mean cumulative dose of 208\u2005mg\/m\u00b2. Digestive toxicity (67%) and obstruction of the excretory tracts of tumoral origin (8%) were aggravating factors. Cisplatin cycle number &gt;3 ( p\u2009=\u20090.04) and dose \u2265330\u2005mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      ( p\u2009=\u20090.04) were the factors associated with cisplatin renal toxicity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      This study concluded that ARF is dose-dependent with the predominance of grade 1 toxicity. A cumulative dose exceeding 330\u2005mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      was correlated with an increased risk of occurrence of ARF.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552231199984","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T02:50:27Z","timestamp":1694141427000},"page":"1023-1028","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Acute renal failure during cisplatin-based chemotherapy: A prospective monocentric study"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4956-9551","authenticated-orcid":false,"given":"Wala","family":"Ben Kridis","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayssa","family":"Lajnef","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afef","family":"Khanfir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Habib Bourguiba Hospital, University of Sfax, Sfax, Tunisia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"bibr1-10781552231199984","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"bibr2-10781552231199984","first-page":"143","volume":"12","author":"Brillet G","year":"1991","journal-title":"Nephrologie"},{"key":"bibr3-10781552231199984","first-page":"99","volume":"70","author":"Almanric K","year":"2017","journal-title":"Can J Hosp Pharm"},{"key":"bibr4-10781552231199984","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071572"},{"key":"bibr5-10781552231199984","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e31812dfe1e"},{"key":"bibr6-10781552231199984","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v17.i30.3510"},{"key":"bibr7-10781552231199984","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600884"},{"key":"bibr8-10781552231199984","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219901305"},{"key":"bibr9-10781552231199984","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3135-6"},{"key":"bibr10-10781552231199984","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00055110"},{"key":"bibr11-10781552231199984","doi-asserted-by":"publisher","DOI":"10.1159\/000510384"},{"key":"bibr12-10781552231199984","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-020-0398-3"},{"key":"bibr13-10781552231199984","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6233-9"},{"key":"bibr14-10781552231199984","doi-asserted-by":"publisher","DOI":"10.1159\/000356587"},{"key":"bibr15-10781552231199984","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b16-00473"},{"key":"bibr16-10781552231199984","volume":"95","author":"Launay-Vacher V","year":"2008","journal-title":"Bull Cancer"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231199984","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231199984","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231199984","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:28:59Z","timestamp":1777688939000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231199984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1177\/10781552231199984"],"URL":"https:\/\/doi.org\/10.1177\/10781552231199984","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]}}}